{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:37:45Z","timestamp":1778661465859,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","medical-hypotheses.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.mehy.2016.11.021","type":"journal-article","created":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T22:26:40Z","timestamp":1481927200000},"page":"26-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Are linear AChR epitopes the real culprit in ocular myasthenia gravis?"],"prefix":"10.1016","volume":"99","author":[{"given":"Xiaorong","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erdem","family":"T\u00fcz\u00fcn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2016.11.021_b0005","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s00415-015-7963-5","article-title":"Myasthenia gravis: a clinical-immunological update","volume":"263","author":"Binks","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.mehy.2016.11.021_b0010","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.coph.2009.04.005","article-title":"Autoimmune disorders of the neuromuscular junction","volume":"9","author":"Lang","year":"2009","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.mehy.2016.11.021_b0015","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jaut.2011.05.006","article-title":"Complement and cytokine based therapeutic strategies in myasthenia gravis","volume":"37","author":"T\u00fcz\u00fcn","year":"2011","journal-title":"J Autoimmun"},{"key":"10.1016\/j.mehy.2016.11.021_b0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/clim.1999.4807","article-title":"Animal models of myasthenia gravis","volume":"94","author":"Christadoss","year":"2000","journal-title":"Clin Immunol"},{"key":"10.1016\/j.mehy.2016.11.021_b0025","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1196\/annals.1405.009","article-title":"Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis","volume":"1132","author":"Christadoss","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.mehy.2016.11.021_b0030","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.4049\/jimmunol.153.11.5330","article-title":"Effect of MHC class I and CD8 cell deficiency on experimental autoimmune myasthenia gravis pathogenesis","volume":"153","author":"Shenoy","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.mehy.2016.11.021_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0008-8749(83)90205-8","article-title":"Cellular immune response to acetylcholine receptors in murine experimental autoimmune myasthenia gravis: inhibition with monoclonal anti-I-A antibodies","volume":"81","author":"Christadoss","year":"1983","journal-title":"Cell Immunol"},{"key":"10.1016\/j.mehy.2016.11.021_b0040","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1084\/jem.184.2.349","article-title":"Both CD4+ and CD8+ T cells are essential to induce experimental autoimmune myasthenia gravis","volume":"184","author":"Zhang","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.mehy.2016.11.021_b0045","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jamaneurol.2015.1444","article-title":"Clinical utility of acetylcholine receptor antibody testing in ocular myasthenia gravis","volume":"72","author":"Peeler","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.mehy.2016.11.021_b0050","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1167\/iovs.07-0271","article-title":"A new mouse model of autoimmune ocular myasthenia gravis","volume":"48","author":"Yang","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.mehy.2016.11.021_b0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/mus.22273","article-title":"Ocular and generalized myasthenia gravis induced by human acetylcholine receptor \u03b3 subunit immunization","volume":"45","author":"Wu","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.mehy.2016.11.021_b0060","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.imlet.2015.10.009","article-title":"Ocular myasthenia gravis induced by human acetylcholine receptor \u220a subunit immunization in HLA DR3 transgenic mice","volume":"168","author":"Wu","year":"2015","journal-title":"Immunol Lett"},{"key":"10.1016\/j.mehy.2016.11.021_b0065","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1172\/JCI14255","article-title":"Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice","volume":"109","author":"Yang","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.mehy.2016.11.021_b0070","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/mus.21371","article-title":"Acetylcholine receptor-alpha subunit expression in myasthenia gravis: a role for the autoantigen in pathogenesis?","volume":"40","author":"Sheng","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.mehy.2016.11.021_b0075","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1212\/WNL.45.3.516","article-title":"The gamma-subunit of the acetylcholine receptor is not expressed in the levator palpebrae superioris","volume":"45","author":"Kaminski","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.mehy.2016.11.021_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2012.04.002","article-title":"CD4 costimulation is not required in a novel LPS-enhanced model of myasthenia gravis","volume":"249","author":"Allman","year":"2012","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.mehy.2016.11.021_b0085","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ana.410220205","article-title":"Acetylcholine receptors in human thymic myoid cells in situ: an immunohistological study","volume":"22","author":"Schluep","year":"1987","journal-title":"Ann Neurol"},{"key":"10.1016\/j.mehy.2016.11.021_b0090","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1749-6632.1998.tb10954.x","article-title":"Muscle nicotinic acetylcholine receptor mRNA expression in hyperplastic and neoplastic myasthenia gravis thymus","volume":"841","author":"MacLennan","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.mehy.2016.11.021_b0095","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.4049\/jimmunol.174.10.5941","article-title":"Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis","volume":"174","author":"Po\u00eba-Guyon","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.mehy.2016.11.021_b0100","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2353\/ajpath.2007.070240","article-title":"Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status","volume":"171","author":"Leite","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.mehy.2016.11.021_b0105","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJM198111263052203","article-title":"Thymus cells in myasthenia gravis selectively enhance production of anti-acetylcholine-receptor antibody by autologous blood lymphocytes","volume":"305","author":"Newsom-Davis","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2016.11.021_b0110","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jneuroim.2004.01.022","article-title":"Thymic myoid cells as a myasthenogenic antigen and antigen-presenting cells","volume":"150","author":"Matsumoto","year":"2004","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.mehy.2016.11.021_b0115","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/ana.21902","article-title":"Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus","volume":"67","author":"Cavalcante","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.mehy.2016.11.021_b0120","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1196\/annals.1405.037","article-title":"Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?","volume":"1132","author":"Soltys","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.mehy.2016.11.021_b0125","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-065X.1998.tb01217.x","article-title":"Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis","volume":"164","author":"Vincent","year":"1998","journal-title":"Immunol Rev"},{"key":"10.1016\/j.mehy.2016.11.021_b0130","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1196\/annals.1254.026","article-title":"Scenarios for autoimmunization of T and B cells in myasthenia gravis","volume":"998","author":"Shiono","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.mehy.2016.11.021_b0135","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987716301803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987716301803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T07:14:23Z","timestamp":1718954063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987716301803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":27,"alternative-id":["S0306987716301803"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2016.11.021","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are linear AChR epitopes the real culprit in ocular myasthenia gravis?","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2016.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}